PanTher Therapeutics

Dan Wildman is president of Wildman Ventures, LLC, and serves as a board member or strategic advisor to several early-stage organizations and publicly held companies. He advises PanTher on its lead candidate, PTM-101, and other Sagittari platform products.

Darshana Zaveri is a Founder and Managing Partner of Catalyst Health Ventures (CHV). She is actively involved in all aspects of fund management including investments and capital raising and has led several investments in the medical device, women’s health and diagnostics markets.

Dave Mackey is the CFO of Catalyst Health Ventures (CHV). He’s responsible for the financial management, reporting, audit, tax, legal and administrative functions of CHV and brings over 20 years of finance, legal, operational and transactional experience to the firm.

Laura Indolfi, PanTher’s co-founder and chief executive officer, invented foundational technology at MIT and Harvard Medical School and led development of PanTher’s Sagittari platform for local delivery of cancer therapeutics to solid tumors.

The company’s mission is to administer therapeutics exclusively at tumor sites to transform clinical outcomes and minimize side effects.

The company says it processes personal information responsibly and safeguards it with technical, administrative, and physical security measures.

PanTher finishes the first patient cohort in its Phase 1b trial of **PTM-101**, an absorbable, high-dose chemotherapy patch designed for **non-metastatic pancreatic cancer**. The trial evaluates the patch’s safety and efficacy as a long-lasting treatment option. Early results exceed expectations, prompting the company to proceed to the next cohort.

Sep 2025MedTech InnovatorNews article

PanTher Therapeutics begins a second clinical trial for its chemotherapy-eluting patch, designed to improve patient tolerance during cancer treatment. The patch delivers chemotherapy directly through the skin, aiming to reduce systemic side effects. The company previously tested similar technology in an earlier trial.

Jul 2025Yahoo FinanceNews article

PanTher Therapeutics begins a Phase 1b clinical trial testing **PTM-101**, an absorbable, long-lasting, high-dose chemotherapy patch designed for localized treatment of pancreatic ductal adenocarcinoma (PDAC). The patch delivers continuous drug administration directly at the tumor site, aiming to redefine cancer therapy by minimizing systemic exposure. The trial marks the first patient treated under this study, advancing PanTher’s portfolio of localized drug formulations.

Jul 2025MedTech InnovatorNews article

PanTher Therapeutics secures FDA clearance to advance its lead drug, **PTM-101**, into a **Phase 1b clinical trial** targeting **pancreatic ductal adenocarcinoma (PDAC)**. The therapy delivers treatment directly and continuously at the tumor site, marking a shift from systemic oncology approaches. The study will evaluate localized administration in patients with this aggressive cancer type.

Aug 2024MedTech InnovatorNews article